BMC cardiovascular disorders

Glucagon-like peptide-1 drugs and the risk of heart rhythm problems in people with heart attack and type 2 diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Ventricular arrhythmia (VA) is a significant factor in sudden cardiac death among patients with acute myocardial infarction (AMI) and type 2 diabetes mellitus (T2DM).

  • VA is linked to increased risk of sudden cardiac death in individuals with AMI and T2DM.
  • Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known to provide cardiovascular benefits.
  • The specific effects of GLP-1RAs on the development of ventricular arrhythmias after AMI remain uncertain.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #59
GLP-1 drugs linked to fewer psychiatric hospitalizations in schizophrenia patients with diabetes
2 weeks ago7 studies
issue #58
A new triple receptor drug cut body weight by nearly 20% in 24 weeks
3 weeks ago7 studies
issue #57
A triple-receptor obesity drug just posted 25–35% weight loss in a phase 3 trial
4 weeks ago7 studies
issue #56
Semaglutide cut heart attack risk by 20% — but weight loss explains less than half of it
5 weeks ago7 studies
issue #55
The brain circuit that makes GLP-1 drugs work also causes nausea — and they can't be separated
6 weeks ago7 studies
issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
7 weeks ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
8 weeks ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
9 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
10 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
11 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief